Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers
Authors
Keywords
PD-1, CTLA-4, PD-L1, Head and neck cancer, Biomarkers, Monoclonal antibodies
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 17, Issue 8, Pages -
Publisher
Springer Nature
Online
2016-06-17
DOI
10.1007/s11864-016-0419-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Immunologic approaches to cancer prevention—current status, challenges, and future perspectives
- (2016) Malgorzata E. Wojtowicz et al. SEMINARS IN ONCOLOGY
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy
- (2016) Jianda Yuan et al. Journal for ImmunoTherapy of Cancer
- Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
- (2015) M. Vassilakopoulou et al. CLINICAL CANCER RESEARCH
- Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
- (2015) Andy Yingjie Lin et al. Journal of Hematology & Oncology
- Immuno-PET of Murine T Cell Reconstitution Postadoptive Stem Cell Transplantation Using Anti-CD4 and Anti-CD8 Cys-Diabodies
- (2015) R. Tavare et al. JOURNAL OF NUCLEAR MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
- (2015) Kyriakos P Papadopoulos et al. Journal for ImmunoTherapy of Cancer
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- The Effect of Radiation on the Immune Response to Cancers
- (2014) Bonggoo Park et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- 64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues
- (2014) Kei Higashikawa et al. PLoS One
- Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo
- (2014) R. Tavare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
- (2014) C. Tang et al. Cancer Immunology Research
- Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer
- (2013) Julie E. Bauman et al. CANCER
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations
- (2011) Kerry S. Campbell et al. IMMUNOLOGY
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now